Duco T Mülder, Hilliene J van de Schootbrugge-Vandermeer, James F O'Mahony, Dianqin Sun, Weiran Han, Rob H A Verhoeven, Marlon van Loo, Wessel van de Veerdonk, Manon C W Spaander, Iris Lansdorp-Vogelaar
{"title":"Gastric Cancer Risk among Immigrants and Socioeconomic Groups in the Netherlands.","authors":"Duco T Mülder, Hilliene J van de Schootbrugge-Vandermeer, James F O'Mahony, Dianqin Sun, Weiran Han, Rob H A Verhoeven, Marlon van Loo, Wessel van de Veerdonk, Manon C W Spaander, Iris Lansdorp-Vogelaar","doi":"10.1158/1055-9965.EPI-24-0889","DOIUrl":"10.1158/1055-9965.EPI-24-0889","url":null,"abstract":"<p><strong>Background: </strong>Identification of groups at a high risk of gastric cancer could facilitate targeted screening in countries with a low gastric cancer incidence. Our aim was to identify such high-risk groups based on individual-level population data on migration history and socioeconomic status (SES) in the Netherlands.</p><p><strong>Methods: </strong>In this retrospective cohort study, patient data from the Netherlands Cancer Registry were linked to demographic data of Statistics Netherlands in the period 2010 to 2022. Gastric cancer incidence rates in the 14 largest immigrant populations were compared with those born in the Netherlands. Odds ratios (OR) were computed per birthplace and controlled for age, sex, and SES. Additionally, we investigated gastric cancer risk among second-generation immigrants and by SES.</p><p><strong>Results: </strong>Immigrant populations at a significantly higher gastric cancer risk compared with the general population were identified. Specifically, foreign-born first-generation immigrants from Bosnia-Herzegovina (OR, 2.42), Turkey (OR, 2.22), and China (OR, 1.92) showed elevated risk. Whereas low SES increased the odds of developing gastric cancer, first-generation immigrants remained at higher risk even after controlling for SES. Second-generation immigrants did not have a significantly higher risk of developing gastric cancer.</p><p><strong>Conclusions: </strong>Certain first-generation immigrants remain at an elevated risk for gastric cancer despite migration to a low-risk region. Identification of these high-risk groups should be used to facilitate targeted gastric cancer prevention.</p><p><strong>Impact: </strong>Potential benefits of targeted Helicobacter pylori test-and-treat policy in immigrant populations should be explored in clinical and modeling studies. Primary care physicians should be cognizant of high-risk groups, facilitating the early detection of cancer within these populations.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"85-92"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wasim Hamad, Bogdan Grigore, Hugo Walford, Jaime Peters, Panos Alexandris, Stefanie Bonfield, Laura Standen, Rachel Boscott, Dawnya Behiyat, Isla Kuhn, Richard D Neal, Fiona M Walter, Natalia Calanzani
{"title":"Biomarkers Suitable for Early Detection of Intrathoracic Cancers in Primary Care: A Systematic Review.","authors":"Wasim Hamad, Bogdan Grigore, Hugo Walford, Jaime Peters, Panos Alexandris, Stefanie Bonfield, Laura Standen, Rachel Boscott, Dawnya Behiyat, Isla Kuhn, Richard D Neal, Fiona M Walter, Natalia Calanzani","doi":"10.1158/1055-9965.EPI-24-0713","DOIUrl":"10.1158/1055-9965.EPI-24-0713","url":null,"abstract":"<p><p>Intrathoracic cancers, including lung cancer, mesothelioma, and thymoma, present diagnostic challenges in primary care. Biomarkers could resolve some challenges. We synthesized evidence on biomarker performance for intrathoracic cancer detection in low-prevalence settings. A search in Embase and MEDLINE included studies that recruited participants with suspected intrathoracic cancer and reported on at least one diagnostic measure for a validated, noninvasive biomarker. Studies were excluded if participants were recruited based on a preestablished diagnosis. A total of 52 studies were included, reporting on 108 individual biomarkers and panels. Carcinoembryonic antigen, CYFRA 21-1, and VEGF were evaluated for lung cancer and mesothelioma. For lung cancer, carcinoembryonic antigen and CYFRA 21-1 were the most studied, with AUCs of 0.48 to -0.90 and 0.48 to -0.83, respectively. Pro-gastrin-releasing peptide (Pro-GRP) and neuron-specific enolase (NSE) had the highest negative predictive values (NPV) (98.2% and 96.9%, respectively), whereas Early Cancer Detection Test - Lung (Early CDT) and miRNA signature classifier panels showed NPVs of 99.3% and 99.0%, respectively, in smokers. For mesothelioma, fibrillin-3 and mesothelin plus osteopontin had AUCs of 0.93 and 0.91, respectively. Thymoma panels (binding AcHR + StrAb and binding AcHR + modulating AcHR + StrAb) had 100% NPVs in patients with myasthenia gravis. The review highlights the performance of some biomarkers. However, few were evaluated in low-prevalence settings. Further evaluation is necessary before implementing these biomarkers for intrathoracic cancers in primary care.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"19-34"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benmei Liu, John R Pleis, Diba Khan, Van L Parsons, Richard Lee, Bill Cai, Machell Town, Eric J Feuer, Yulei He
{"title":"Small Area Estimation of PSA Testing in US States and Counties.","authors":"Benmei Liu, John R Pleis, Diba Khan, Van L Parsons, Richard Lee, Bill Cai, Machell Town, Eric J Feuer, Yulei He","doi":"10.1158/1055-9965.EPI-24-1086","DOIUrl":"10.1158/1055-9965.EPI-24-1086","url":null,"abstract":"<p><strong>Background: </strong>In 2012, the US Preventive Services Task Force recommended against prostate cancer screening using the PSA test for all age groups. In 2018, the US Preventive Services Task Force's recommendation shifted from a \"D\" (not recommended) to a \"C\" (selectively offering PSA-based screening based on professional judgment and patient preferences) in men ages 55 to 69. Limited reliable county-level prostate cancer screening data are available for cancer surveillance purposes.</p><p><strong>Methods: </strong>Utilizing data from the National Health Interview Survey (NHIS) and Behavioral Risk Factor Surveillance System (BRFSS) collected in 2012 to 2019, state- and county-level small area models were developed for estimating PSA testing. Model diagnosis, internal validation, and external validation examining associations of PSA testing and prostate cancer incidence were conducted.</p><p><strong>Results: </strong>Model-based estimates of PSA testing rates were produced for all US states and 3,142 counties for two data periods: 2012 to 2016 and 2018 to 2019. Geographic variations across counties were demonstrated through maps. Moderate positive correlations between PSA-based screening and prostate cancer incidence were observed, e.g., the state-level weighted Pearson's correlation coefficients were 0.5025 (P value = 0.0002) and 0.3691 (P value = 0.0077) for 2012 to 2016 and 2018 to 2019, respectively.</p><p><strong>Conclusions: </strong>These modeled estimates showed improved precision and adjusted for the differences between the BRFSS and NHIS. The approach of combining the NHIS and BRFSS utilized strengths of the larger sample size of the BRFSS and generally higher response rates and better household coverage from the NHIS.</p><p><strong>Impact: </strong>The resulting small area estimates offer a valuable resource for the cancer surveillance community, aiding in targeted interventions, decision making, and further research endeavors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"197-204"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi
{"title":"Changes in Breast Cancer Screening Prevalence in the United States during the COVID-19 Pandemic, 2018 to 2022.","authors":"Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi","doi":"10.1158/1055-9965.EPI-24-0540","DOIUrl":"10.1158/1055-9965.EPI-24-0540","url":null,"abstract":"<p><strong>Background: </strong>Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared with 2018 in the national prevalence of self-reported up-to-date mammography.</p><p><strong>Methods: </strong>Using 2018 to 2022 data from the Center for Disease Control and Prevention's Behavioral Risk Factor Surveillance System, we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (biannual mammography in women of ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.</p><p><strong>Results: </strong>UTD breast cancer screening declined for the first time since 2018 [2018 compared with 2022, from 78.7%-76.6%; aPR, 0.97; 95% confidence interval (CI), 0.96-0.98] despite a small increase in past-year breast cancer screening from 2020 to 2022 (57.9%-59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended breast cancer screening in 2022 versus 2018. UTD breast cancer screening declines between 2018 and 2022 were largest for American Indian/Alaska Native women (74.8%-62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (< high school: 73.1%-65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48%-42.9%; aPR, 0.85; 95% CI, 0.78-0.92).</p><p><strong>Conclusions: </strong>Previously noted pandemic-related declines in past-year breast cancer screening now reflect in women reporting being UTD, with the largest declines in American Indian/Alaska Native women and those with lower socioeconomic status.</p><p><strong>Impact: </strong>Future studies should monitor screening prevalence in relation to breast cancer diagnostic stage overall and by sociodemographic groups.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"133-138"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew T Warkentin, Winson Y Cheung, Darren R Brenner, Dylan E O'Sullivan
{"title":"Risk of Developing a Subsequent Primary Cancer among Adult Cancer Survivors.","authors":"Matthew T Warkentin, Winson Y Cheung, Darren R Brenner, Dylan E O'Sullivan","doi":"10.1158/1055-9965.EPI-24-0636","DOIUrl":"10.1158/1055-9965.EPI-24-0636","url":null,"abstract":"<p><strong>Background: </strong>Improvements in cancer control have led to a drastic increase in cancer survivors who may be at an elevated risk of developing subsequent primary cancers (SPC). In this study, we assessed the risk and patterns of SPC development among 196,858 adult cancer survivors in Alberta, Canada.</p><p><strong>Methods: </strong>We used data from the Alberta Cancer Registry to identify all first primary cancers occurring between 2004 and 2020. A SPC was considered as the next primary cancer occurring in a different site. We estimated standardized incidence ratios (SIR) for SPC development as the observed number of SPC (O) divided by the expected number of SPC (E), in which E is a weighted sum of the population-based year-age-sex-specific incidence rates and the corresponding person-years of follow-up.</p><p><strong>Results: </strong>The risk of developing a SPC up to 15 years after an initial cancer was 16.2% for males and 12.2% for females. Overall, both males (SIR = 1.50) and females (SIR = 1.58) had an increased risk of a SPC. There were significant increases in SPC risk for nearly all age groups, with a greater than five-fold increase for survivors diagnosed between ages 18 and 39. Screen-detectable cancers including colorectal, lung, cervix, and breast accounted for 46% and 27% of SPC among females and males, respectively.</p><p><strong>Conclusions: </strong>Cancer survivors of nearly every initial site had substantially increased risk of a SPC, compared with the cancer risk in the general population.</p><p><strong>Impact: </strong>Screen-detectable cancers were common SPC sites and highlight the need to investigate optimal strategies for screening the growing population of cancer survivors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"174-181"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rebecca D Kehm, Jeanine M Genkinger, Julia A Knight, Robert J MacInnis, Yuyan Liao, Shuai Li, Prue C Weideman, Wendy K Chung, Allison W Kurian, Sarah V Colonna, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, John L Hopper, Mary Beth Terry
{"title":"Physical Activity during Adolescence and Early Adulthood and Breast Cancer Risk before Age 40 Years.","authors":"Rebecca D Kehm, Jeanine M Genkinger, Julia A Knight, Robert J MacInnis, Yuyan Liao, Shuai Li, Prue C Weideman, Wendy K Chung, Allison W Kurian, Sarah V Colonna, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, John L Hopper, Mary Beth Terry","doi":"10.1158/1055-9965.EPI-24-0743","DOIUrl":"10.1158/1055-9965.EPI-24-0743","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer incidence is increasing in women under age 40, underscoring the need for research on breast cancer risk factors for younger women.</p><p><strong>Methods: </strong>We used data from an international family cohort (n = 26,348) to examine whether recreational physical activity (RPA) during adolescence and early adulthood is associated with breast cancer risk before age 40. The cohort includes 2,502 women diagnosed with breast cancer before age 40, including 2,408 diagnosed before study enrollment (68% within 5 years of enrollment). Women reported their average hours per week of moderate and strenuous RPA during adolescence (12-17 years) and early adulthood (25-34 years), which were converted to total age-adjusted metabolic equivalents per week and categorized into quartiles. We conducted attained age analyses until age 40 (follow-up time began at age 18) using Cox proportional hazards regression models adjusted for study center, race and ethnicity, and education.</p><p><strong>Results: </strong>Being in the highest versus lowest quartile of RPA during adolescence and early adulthood were respectively associated with 12% [HR (95% confidence interval, or CI), 0.88 (0.78-0.98)] and 16% [HR (95% CI), 0.84 (0.74-0.95) lower breast cancer risks before age 40. Being in the highest quartile of RPA during both adolescence and early adulthood (Pearson correlation = 0.52) versus neither time point was associated with a 22% lower risk [HR (95% CI), 0.78 (0.68-0.89)].</p><p><strong>Conclusions: </strong>Findings suggest that RPA during adolescence and early adulthood may lower breast cancer risk before age 40.</p><p><strong>Impact: </strong>Policies promoting physical activity during adolescence and early adulthood may be important for reducing the growing burden of breast cancer in younger women.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"108-116"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul L Reiter, Abigail B Shoben, Sarah Cooper, Amie M Ashcraft, Emma McKim Mitchell, Mark Dignan, Mark Cromo, Jean Walunis, Deborah Flinner, Dannell Boatman, Lindsay Hauser, Mack T Ruffin, Jerome L Belinson, Roger T Anderson, Stephenie Kennedy-Rea, Electra D Paskett, Mira L Katz
{"title":"A Mail-Based HPV Self-Collection Program to Increase Cervical Cancer Screening in Appalachia: Results of a Group Randomized Trial.","authors":"Paul L Reiter, Abigail B Shoben, Sarah Cooper, Amie M Ashcraft, Emma McKim Mitchell, Mark Dignan, Mark Cromo, Jean Walunis, Deborah Flinner, Dannell Boatman, Lindsay Hauser, Mack T Ruffin, Jerome L Belinson, Roger T Anderson, Stephenie Kennedy-Rea, Electra D Paskett, Mira L Katz","doi":"10.1158/1055-9965.EPI-24-0999","DOIUrl":"10.1158/1055-9965.EPI-24-0999","url":null,"abstract":"<p><strong>Background: </strong>Despite the promise of mail-based human papillomavirus (HPV) self-collection programs for increasing cervical cancer screening, few have been evaluated in the United States. We report the results of a mail-based HPV self-collection program for underscreened women living in Appalachia.</p><p><strong>Methods: </strong>We conducted a group randomized trial from 2021 to 2022 in the Appalachian regions of Kentucky, Ohio, Virginia, and West Virgnia. Participants were women of ages 30 to 64 years who were underscreened for cervical cancer and from a participating health system. Participants in the intervention group (n = 464) were mailed an HPV self-collection kit followed by telephone-based patient navigation (if needed), and participants in the usual care group (n = 338) were mailed a reminder letter to get a clinic-based cervical cancer screening test. Generalized linear mixed models compared cervical cancer screening between the study groups.</p><p><strong>Results: </strong>Overall, 14.9% of participants in the intervention group and 5.0% of participants in the usual care group were screened for cervical cancer. The mail-based HPV self-collection intervention increased cervical cancer screening compared with the usual care group (OR, 3.30; 95% confidence interval, 1.90-5.72; P = 0.005). One or more high-risk HPV types were detected in 10.5% of the returned HPV self-collection kits. Among the participants in the intervention group whom patient navigators attempted to contact, 44.2% were successfully reached.</p><p><strong>Conclusions: </strong>HPV self-collection increased cervical cancer screening, and future efforts are needed to determine how to optimize such programs, including the delivery of patient navigation services.</p><p><strong>Impact: </strong>Mail-based HPV self-collection programs are a viable strategy for increasing cervical cancer screening among underscreened women living in Appalachia.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"159-165"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antoine Dubray-Vautrin, Guillaume Rougier, Christophe Le Tourneau, Wahib Ghanem, Nathalie Badois, Maria Lesnik, Baptiste Sabran, Laurence Bozec, Joey Martin, Olivier Choussy
{"title":"Biomarkers and Prognostic Stratification of Squamous Cell Carcinoma of the Oral Cavity in Young Adults: How to Personalize Therapeutic Management?","authors":"Antoine Dubray-Vautrin, Guillaume Rougier, Christophe Le Tourneau, Wahib Ghanem, Nathalie Badois, Maria Lesnik, Baptiste Sabran, Laurence Bozec, Joey Martin, Olivier Choussy","doi":"10.1158/1055-9965.EPI-24-1091","DOIUrl":"10.1158/1055-9965.EPI-24-1091","url":null,"abstract":"<p><p>Squamous cell carcinomas of the oral cavity in young adults represent a heterogeneous entity. New prognostic biomarkers are described in the literature. The aim of this review was to identify emerging biomarkers and prognostic stratification factors of young population. Clinical, biological, microbiological, histopathologic, and molecular markers statistically associated with overall survival (OS) and disease-free survival and were validated in literature. Young adults <40 years of age who were nonsmokers showed a marginally worse prognosis, whereas those <30 years of age showed unfavorable prognosis compared with those with >30 years of age. The high rate of neutrophil-to-lymphocyte ratio was associated with decreased 5-year disease-specific survival, PD-L1 expression correlated with improved OS and recurrence-free survival, and the presence of Fusobacterium and mutations in p53, cyclin D1, and VEGF were associated with reduced OS. Combining these markers in young adults with oral cavity squamous cell carcinomas should be used to adapt the intensification of therapy in addition to the tumor-node-metastasis classification and minor histoprognostic factors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"14-18"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alon Simchovitz Gesher, Keren Grinin, Dor Atias, Tal Patalon, Sivan Gazit, Moshe Hoshen, Amir Dagan
{"title":"Strength in Numbers: Identifying a Significant Association between High Serum Ferritin Levels and Newly Diagnosed Malignancy in a Large Health Organization Cohort.","authors":"Alon Simchovitz Gesher, Keren Grinin, Dor Atias, Tal Patalon, Sivan Gazit, Moshe Hoshen, Amir Dagan","doi":"10.1158/1055-9965.EPI-24-0757","DOIUrl":"10.1158/1055-9965.EPI-24-0757","url":null,"abstract":"<p><strong>Background: </strong>Ferritin, an iron storage protein and acute phase reactant, has been implicated in various aspects of human health and disease, including cancer. Previous studies have identified elevated serum ferritin (SF) levels in several cancer types, but a comprehensive examination across different malignancies remains lacking. This study aims to fill this gap by utilizing anonymized data from Maccabi Health Services (MHS), one of Israel's largest health organizations, to explore the association between elevated SF levels and the diagnosis of different malignancies.</p><p><strong>Methods: </strong>An extensive dataset from MHS, comprising 2.7 million members, including 1.3 million individuals who underwent SF level testing, was analyzed. ORs and 95% confidence intervals were calculated to assess the association between high SF levels and cancer diagnosis. Subgroup analysis was conducted to investigate variations across different malignancies.</p><p><strong>Results: </strong>The analysis revealed a significant association between elevated SF levels and cancer diagnosis among MHS members, with an OR of 1.9 (95% confidence interval, 1.71-2.15). Subgroup analysis unveiled differences in the association across malignancy types, with hematologic, hepatobiliary, and respiratory malignancies more strongly associated with high SF levels.</p><p><strong>Conclusions: </strong>This study provides further support for the link between elevated SF levels and malignancy, leveraging a vast dataset from MHS, underscoring potential utilities of elevated SF levels as a potential indicator for cancer with a variable role among different malignancy types.</p><p><strong>Impact: </strong>The identification of elevated SF levels as a potential indicator for underlying malignancy for seemingly healthy individuals.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"190-196"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yingmiao Liu, Jiatong Li, Jing Lyu, Lauren E Howard, Alexander B Sibley, Mark D Starr, John C Brady, Christy Arrowood, Elise C Kohn, S Percy Ivy, Herbert I Hurwitz, James L Abbruzzese, Kouros Owzar, Andrew B Nixon
{"title":"Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants.","authors":"Yingmiao Liu, Jiatong Li, Jing Lyu, Lauren E Howard, Alexander B Sibley, Mark D Starr, John C Brady, Christy Arrowood, Elise C Kohn, S Percy Ivy, Herbert I Hurwitz, James L Abbruzzese, Kouros Owzar, Andrew B Nixon","doi":"10.1158/1055-9965.EPI-24-0644","DOIUrl":"10.1158/1055-9965.EPI-24-0644","url":null,"abstract":"<p><strong>Background: </strong>Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants.</p><p><strong>Methods: </strong>The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors.</p><p><strong>Results: </strong>ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045).</p><p><strong>Conclusions: </strong>Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay.</p><p><strong>Impact: </strong>These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"93-99"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}